Non-alcoholic fatty liver disease (NAFLD) shares a close relationship with cardiovascular morbidity and mortality. The purpose of this study is to evaluate the frequency of NAFLD in the patients with non-diabetic chronic kidney disease (CKD).
This cross-sectional study included 80 patients with non-diabetic CKD, of which, 50 patients were on hemodialysis (HD) and 30 patients had CKD stage G3–5 not on dialysis. These patients were randomly selected from Ain Shams University Hospitals, Cairo, Egypt. Patients with diabetes mellitus, obesity, alcohol intake, viral hepatitis, or drug-induced liver steatosis were excluded from this study. Importantly, the controlled attenuation parameter (CAP) (dB/m) of liver steatosis (S0–S3) and liver stiffness/fibrosis measurement (F0–F4) were measured using transient elastography (Fibroscan®). Other evaluations included complete blood count, routine blood chemistry, and C-reactive protein (CRP) titer.
In total, 45 (56.25%) (30 males, 15 females) out of total 80 studied patients were reported to have NAFLD. There were 29 patients with end-stage renal disease who were on regular HD and 16 patients with pre-dialysis CKD G3–5. The mean CAP values of hepatic steatosis in the patients with CKD on dialysis and patients with pre-dialysis CKD were 265.41 ± 52.73 and 259 ± 44.8 dB/m, respectively. A significant association between the severity of hepatic steatosis degree with decreased glomerular filtration rate and increased CKD stage was observed in this study. The degree of liver stiffness was significantly related to an increased hepatic steatosis grade. A significant positive correlation was found between the degree of NAFLD and serum levels of alanine aminotransferase, aspartate transaminase, total cholesterol, triglycerides, low-density lipoprotein, and CRP titer (P < 0.05). Importantly, NAFLD was significantly associated with an evident history of cardiovascular disease (CVD) among the studied patients.
A high frequency of NAFLD (56%) was observed among the patients with non-diabetic CKD on hemodialysis and patients with pre-dialysis CKD. NAFLD may be associated with an increased liver stiffness grade and CVD among those patients.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Chalasani N, Chalasani N, Younossi Z, Lavine JE et al (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55(6):2005–2023. https://doi.org/10.1002/hep.25762
Dowman JK, Tomlinson JW, Newsome PN (2011) Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic fatty steatosis. AP&T 33:525–540. https://doi.org/10.1111/j.1365-2036.2010.04556
Centres for Disease Control and Prevention (2019) Chronic kidney disease surveillance system website. https://nccd.cdc.gov/CKD. Accessed 7 Jan 2019
Alani H, Tamimi A, Tamimi N (2014) Cardiovascular co-morbidity in chronic kidney disease: current knowledge and future research needs. World J Nephrol 3(4):156–168. https://doi.org/10.5527/wjn.v3.i4.156
Targher G, Bertolini L, Rodella S, Zoppini G, Lippi G, Day C, Muggeo M (2008) Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia 51(3):444–450. https://doi.org/10.1007/s00125-007-0897-4
Targher G, Bertolini L, Rodella S, Lippi G, Zoppini G, Chonchol M (2010) Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. CJASN 5(12):2166–2171. https://doi.org/10.2215/CJN.05050610
Targher G, Chonchol MB, Byrne CD (2014) CKD and non-alcoholic fatty liver disease. Am J Kidney Dis 64(4):638–652. https://doi.org/10.1053/j.ajkd.2014.05.019
Mikolasevic I, Lukenda V, Racki S, Milic S, Sladoje-Martinovic B, Orlic L (2014) Nonalcoholic fatty liver disease (NAFLD)–a new factor that interplays between inflammation, malnutrition, and atherosclerosis in elderly hemodialysis patients. Clin Interv Aging 9:1295–1303. https://doi.org/10.2147/CIA.S65382
Wang Y, Fan Q, Wang T, Wen J, Wang H, Zhang T (2015) Controlled attenuation parameter for assessment of hepatic steatosis grades: a diagnostic meta-analysis. Int J Clin Exp Med 8(10):17654–17663
Shi KQ, Tang JZ, Zhu XL et al (2014) Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: a meta-analysis of diagnostic accuracy. J Gastroenterol Hepatol 29(6):1149–1158. https://doi.org/10.1111/jgh.12519
WHO Expert Committee: physical status (1995) The use and interpretation of anthropometry: report of a WHO expert committee (WHO Technical Report Series; 854) Geneva. World health organ Tech. Rep. Ser., vol 854, pp 1–452
National Kidney Foundation (2001) K/DQQI clinical practice guidelines for hemodialysis adequacy. Am J Kidney Dis 37:S7–S64. https://doi.org/10.1053/ajkd.2001.20777
Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612. https://doi.org/10.7326/0003-4819-150-9-200905050-00006
Sasso M, Beaugrand M, de Ledinghen V et al (2010) Controlled attenuation parameter (CAP): a novel VCTEŮ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 36(11):1825–1835. https://doi.org/10.1016/j.ultrasmedbio.2010.07.005
de Lédinghen V, Vergniol J (2008) Transient elastography (FibroScan®). Gastroenterol Clin Biol 32(6):58–67. https://doi.org/10.1016/S0399-8320(08)73994-0
Bang KB, Cho YK (2015) Comorbidities and metabolic derangement of NAFLD. J Lifestyle Med 5(1):7–13. https://doi.org/10.15280/jlm.2015.5.1.7
Orli L, Mikolasevic I, Bagic Z, Racki S, Stimac D, Milic S (2015) Chronic kidney disease and nonalcoholic fatty liver disease—is there a link? Wien Klin Wochenschr 127:451–458. https://doi.org/10.1007/s00508-015-0757-z
Mikolasevic I, Orlic L, Zaputovic L et al (2015) Usefulness of liver test and controlled attenuation parameter in detection of nonalcoholic fatty liver disease in patients with chronic renal failure and coronary heart disease. Wien Klin Wochenschr 127(11–12):451–458. https://doi.org/10.1007/s00508-015-0757-z
Jang HR, Kang D, Sinn DH et al (2018) Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study. Sci Rep 8(1):4718. https://doi.org/10.1038/s41598-018-23014-0
Mikolasevic I, Racki S, Bubic I, Jelic I, Stimac D, Orlic L (2013) Chronic kidney disease and nonalcoholic Fatty liver disease proven by transient elastography. Kidney Blood Press Res 37(4–5):305–310. https://doi.org/10.1159/000350158
Yoon CY, Lee M, Kim SU et al (2017) Fatty liver associated with metabolic derangement in patients with chronic kidney disease: a controlled attenuation parameter study. Kidney Res Clin Pract 36(1):48–57
Hwang ST, Cho YK, Yun JW et al (2010) Impact of nonalcoholic fatty liver disease on microalbuminuria in patients with prediabetes and diabetes. Intern Med J 40(6):437–442. https://doi.org/10.1111/j.1445-5994.2009.01979.x
Cruz MA, Cruz JF, Macena LB, de Santana DS, Oliveira CC, Lima SO, Franca AV (2015) Association of the Nonalcoholic Hepatic Steatosis and its degrees with the values of liver enzymes and HOMA-IR index. Gastroenterol Res 8(5):260–264
Ray L, Nanda SK, Chatterjee A, Sarangi R, Ganguly S (2015) A comparative study of serum aminotransferases in chronic kidney disease with and without end-stage renal disease: need for new reference ranges. Int J Appl Basic Med Res 5(1):31–35. https://doi.org/10.4103/2229-516X.149232
Lee TY, Wu JC, Yu SH, Lin JT, Wu MS, Wu CY (2017) The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease. Int J Cancer 141(7):1307–1314. https://doi.org/10.1002/ijc.30784
Jeong H, Baek SY, Kim SW, Park EJ, Lee J, Kim H, Jeon CH (2019) C reactive protein level as a marker for dyslipidaemia, diabetes and metabolic syndrome: results from the Korea National Health and Nutrition Examination Survey. BMJ Open 9(8):e029861. https://doi.org/10.1136/bmjopen-2019-029861
Chan DT, Dogra GK, Irish AB, Ooi EM, Barrett PH, Chan DC, Watts GF (2009) Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-III. J Lipid Res 50(12):2524–2531. https://doi.org/10.1194/jlr.P900003-JLR200
Lee SH, Yun SJ, Kim DH, Jo HH, Park YS (2017) Severity of non-alcoholic fatty liver disease on sonography and risk of coronary heart disease. J Clin Ultrasound 45(7):391–399. https://doi.org/10.1002/jcu.22472
Sesti G, Fiorentino TV, Arturi F, Perticone M, Sciacqua A, Perticone F (2014) Association between non invasive fibrosis markers and chronic kidney disease among adults with non alcoholic fatty liver disease. PLoS ONE 9(2):e88569. https://doi.org/10.1371/journal.pone.0088569
No funding was received for conducting this study.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Behairy, M.A., Sherief, A.F. & Hussein, H.A. Prevalence of non-alcoholic fatty liver disease among patients with non-diabetic chronic kidney disease detected by transient elastography. Int Urol Nephrol (2021). https://doi.org/10.1007/s11255-021-02815-9
- Non-alcoholic fatty liver
- Liver stiffness